Table 1 Characteristics of included studies of glucocorticoids in cardiac arrest
Study details | Mentzelopoulos et al. [28] | Mentzelopoulos et al. [27] | Andersen et al. [26] |
|---|---|---|---|
Country | Greece | Greece | Denmark |
Period of enrollment | 2005 to 2006 | 2008 to 2010 | 2018 to 2021 |
Type of population | |||
In-hospital | ✓ | ✓ | ✓ |
Sample size, N | 100 | 268 | 501 |
Cases for analysis, N | |||
VSE group | 48 | 130 | 237 |
Control group | 52 | 138 | 264 |
Age, y | |||
VSE group | 65.5 ± 17.7 | 63.2 ± 17.6 | 71.0 ± 13.0 |
Control group | 69.2 ± 17.7 | 62.8 ± 18.6 | 70.0 ± 12.0 |
Male gender, % | |||
VSE group | 63 | 73.1 | 62 |
Control group | 56 | 63.8 | 66 |
Study design | |||
Prospective RCTs | ✓ | ✓ | ✓ |
Inclusion and exclusion criteria defined | ✓ | ✓ | ✓ |
Excluded patients specified | ✓ | ✓ | ✓ |
Relevant baseline characteristics | ✓ | ✓ | ✓ |
Reporting | |||
ROSC | ✓ | ✓ | ✓ |
Survival | ✓ | ✓ | ✓ |
MAP during and after CPR | ✓ | ✓ | |
Ventilator free days | ✓ | ✓ | ✓ |
Organ failure free days | ✓ | ✓ | |
Complication and Adverse events | ✓ | ✓ | ✓ |
Neurologic Outcome | ✓ | ✓ | ✓ |